Vasculitis and Giant Cell Arteritis News

SAN DIEGO — Patients with granulomatosis with polyangiitis and microscopic polyangiitis who lower their glucocorticoid dose have an increased risk for death, renal failure, progression or relapse, said a presenter at ACR Convergence 2023.

SAN DIEGO — Trimethoprim sulfamethoxazole prophylaxis halves serious infection risk in patients with granulomatosis with polyangiitis receiving B-cell depletion with rituximab, according to data presented at ACR Convergence 2023.

Patients with suspected giant cell arteritis should undergo an ultrasound as the first-line imaging method, according to updated EULAR recommendations published in the Annals of the Rheumatic Diseases.

The FDA has granted 510(k) clearance to Werfen for its Aptiva Connective Tissue Disease Essential reagent to assist in the diagnosis of patients with autoimmune diseases, according to a manufacturer press release.

The prevalence of neuropsychiatric symptoms in patients with systemic autoimmune rheumatic diseases is significantly “higher and more wide-ranging” than previously recognized, according to data published in Rheumatology.

Patients with new or relapsing granulomatosis with polyangiitis or microscopic polyangiitis should receive rituximab over cyclophosphamide, according to new recommendations from the Pan American League of Associations for Rheumatology.

Patients with inflammatory rheumatic diseases are as likely as the general population to contract COVID-19, but are at a higher risk for severe outcomes, including hospitalization and death, according to data.

SAN DIEGO — Clinical trials exploring intravenous immunoglobulin and Janus kinase inhibition headline a robust pipeline for idiopathic inflammatory myopathies, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

SAN DIEGO — The future of ANCA-associated vasculitis management appears promising, as upcoming therapies will likely address current unmet needs, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

SAN DIEGO — A growing body of clinical trial data are increasingly guiding the treatment landscape for giant cell and Takayasu arteritis, according to a presenter at the 2023 Congress of Clinical Rheumatology West.